In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug
Published
The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. The new label recommends that the drug be given only to patients with mild symptoms.
Full Article